Esperion Therapeutics logo

Esperion TherapeuticsNASDAQ: ESPR

Profile

Sector:

Healthcare

Country:

United States

IPO:

26 June 2013

Next earnings report:

27 February 2025

Last dividends:

N/A

Next dividends:

N/A
$421.66 M
-33%vs. 3y high
63%vs. sector
-vs. 3y high
-vs. sector
-442%vs. 3y high
10%vs. sector
-83%vs. 3y high
31%vs. sector

Price

after hours | Sat, 16 Nov 2024 00:43:32 GMT
$2.14+$0.03(+1.42%)

Dividend

No data over the past 3 years
$51.63 M$62.35 M
$51.63 M-$29.52 M

Analysts recommendations

Institutional Ownership

ESPR Latest News

Esperion Therapeutics: Growth Initiatives Are Paying Off - Buy
seekingalpha.com13 November 2024 Sentiment: POSITIVE

I maintain my buy rating on Esperion Therapeutics due to its strong Q3 2024 financial performance, showcasing consistent revenue growth and market adoption. The Company's aggressive commercialization efforts, including market coverage expansion and sales force growth, have significantly boosted retail prescriptions and broadened future revenue streams. International expansion through partnerships with Daiichi Sankyo Europe and Otsuka Pharmaceutical has driven prescription and revenue growth, strengthening ESPR's global presence.

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
globenewswire.com08 November 2024 Sentiment: POSITIVE

ANN ARBOR, Mich., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on November 7, 2024, the Company granted four new employees 12,900 restricted stock units (RSUs) under Esperion's 2017 Inducement Equity Incentive Plan.

Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update
globenewswire.com07 November 2024 Sentiment: POSITIVE

– Total Revenue Increased 52% Year-over-Year to $51.6 Million with  U.S. Net Product Revenue of $31.1 Million, Representing 53% Growth –

Esperion to Report Third Quarter 2024 Financial Results on November 7
globenewswire.com24 October 2024 Sentiment: NEUTRAL

ANN ARBOR, Mich., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2024 financial results before the market opens on Thursday, November 7, 2024.

Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
globenewswire.com25 September 2024 Sentiment: POSITIVE

ANN ARBOR, Mich., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on September 23, 2024, the Company granted one new employee 3,500 restricted stock units (RSUs) under Esperion's 2017 Inducement Equity Incentive Plan.

Why Is Esperion Therapeutics (ESPR) Down 3.9% Since Last Earnings Report?
zacks.com11 September 2024 Sentiment: NEUTRAL

Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock?

Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)
globenewswire.com03 September 2024 Sentiment: POSITIVE

– New Additions to Medicare Formularies at Optum/United AARP and CVS/SilverScript Coupled with Humana Provides Access to More Than 65% of Medicare Insured Lives and More Than 92% of Commercially Insured Lives –

Esperion Therapeutics: Delivering On Expectations While Navigating Overhangs
seekingalpha.com19 August 2024 Sentiment: POSITIVE

Meeting expectations with revenue growth, expense guidance, and sales execution. Potential overhang from financial engineering with complex deals, warrants, and generic litigants. Maintaining a buy rating for Esperion Therapeutics, Inc. based on current execution and expanding international scope.

Esperion Therapeutics: Strategically Positioned To Grow
seekingalpha.com16 August 2024 Sentiment: POSITIVE

Esperion is a pharmaceutical firm whose focus is to treat patients with high low-density lipoprotein cholesterol (LDL-C). I rate it a buy due to strategic initiatives and market potential driving significant growth. Strong revenue growth and margin expansions reflect improving financial performance and market breakthrough.

Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates
zacks.com12 August 2024 Sentiment: POSITIVE

Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.46 per share a year ago.

  • 1(current)
  • 2
  • 3

What type of business is Esperion Therapeutics?

Esperion Therapeutics, Inc. is a pharmaceutical company engaged in the development and commercialization of oral non-statin medications for the treatment of patients with high levels of low-density lipoprotein cholesterol (LDL-C). The company was founded in 2008 and is headquartered in Ann Arbor, Michigan. The company's lead product candidates are the combination tablets NEXLETOLTM (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) - oral non-statin medications for lowering LDL-C levels in patients with atherosclerotic cardiovascular disease and heterozygous familial hypercholesterolemia.

What sector is Esperion Therapeutics in?

Esperion Therapeutics is in the Healthcare sector

What industry is Esperion Therapeutics in?

Esperion Therapeutics is in the Drug Manufacturers - Specialty & Generic industry

What country is Esperion Therapeutics from?

Esperion Therapeutics is headquartered in United States

When did Esperion Therapeutics go public?

Esperion Therapeutics initial public offering (IPO) was on 26 June 2013

What is Esperion Therapeutics website?

https://www.esperion.com

Is Esperion Therapeutics in the S&P 500?

No, Esperion Therapeutics is not included in the S&P 500 index

Is Esperion Therapeutics in the NASDAQ 100?

No, Esperion Therapeutics is not included in the NASDAQ 100 index

Is Esperion Therapeutics in the Dow Jones?

No, Esperion Therapeutics is not included in the Dow Jones index

When was Esperion Therapeutics the previous earnings report?

No data

When does Esperion Therapeutics earnings report?

The next expected earnings date for Esperion Therapeutics is 27 February 2025